atropine
Approved
Sep 15, 1960
Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors. — NCATS
Clinical trial activity
197 trials · 184 clinical orgs · 66 marketing orgs
Earliest trial started Dec 1, 1996 (NCT00748059)
Timeline
1960s
- Sep 15, 1960
Pfizer — Earliest FDA Approval
- Sep 15, 1960
G D Searle — Marketing Organization
- Sep 15, 1960
Pfizer — NDA Secondary Org
- Sep 15, 1960
Pfizer — NDA Organization
- Oct 19, 1961
G D Searle — NDA Secondary Org
1970s
- May 15, 1973
Meridien Medical Technologies, Inc. — NDA Secondary Org
- May 15, 1973
MMT — NDA Secondary Org
- Apr 18, 1977
MD Pharma — Marketing Organization
- Jun 3, 1977
Sun Pharmaceuticals — Marketing Organization
- Jun 7, 1977
Fosun — Marketing Organization
- Jul 5, 1977
R&S Pharma — Marketing Organization
- Jan 27, 1978
Lumara Health — Marketing Organization
- Feb 13, 1978
Medpointe — Marketing Organization
- Feb 21, 1978
Lannett Company, Inc. — Marketing Organization
- Mar 9, 1978
Inwood Laboratories — Marketing Organization
- Jun 22, 1978
Watson Pharmaceuticals — Marketing Organization
- Jul 14, 1978
Sebela Pharmaceuticals — Marketing Organization
- Jul 14, 1978
Sebela Pharmaceuticals — NDA Secondary Org
- Dec 22, 1978
Mylan — Marketing Organization
- Oct 29, 1979
Ani Pharmaceuticals — Marketing Organization
1980s
- Apr 6, 1981
R.P. Scherer — Marketing Organization
- Jul 17, 1981
Parke-Davis — Marketing Organization
- Jul 17, 1981
Warner Lambert — Marketing Organization
- Mar 15, 1982
Hikma — Marketing Organization
- May 3, 1982
West-Ward Pharmaceutical — Marketing Organization
- Sep 9, 1982
Lederle — Marketing Organization
- Sep 9, 1982
American Cyanamid — Marketing Organization
- Mar 25, 1983
Vanguard — Marketing Organization
- May 10, 1985
Superpharm — Marketing Organization
- Jan 30, 1987
AbbVie — Marketing Organization
1990s
- Sep 19, 1990
United States Army — NDA Secondary Org
- Nov 6, 1991
Mylan — NDA Secondary Org
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
- Mar 5, 1997
Bausch Health Companies — Marketing Organization
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
2000s
- May 2, 2000
Strides Pharma Science — Marketing Organization
- May 2, 2000
Par Pharmaceuticals — Marketing Organization
- Nov 27, 2000
Able Laboratories — Marketing Organization
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
- Jul 9, 2001
Hospira — NDA Secondary Org
- Sep 28, 2006
Meridien Medical Technologies, Inc. — Marketing Organization
2010s
- Jul 18, 2014
Akorn, Inc. — NDA Secondary Org
- Jul 18, 2014
Rising Pharmaceuticals — Marketing Organization
- Dec 1, 2016
Alcon — NDA Secondary Org
- Dec 1, 2016
Nestle — NDA Secondary Org
- Jan 26, 2018
Fresenius — NDA Secondary Org
- Jul 9, 2018
Rafa Laboratories — NDA Secondary Org
- Aug 31, 2018
Upsher-Smith Laboratories — Marketing Organization
- Nov 13, 2018
Bayshore Pharms Llc — Marketing Organization
- Nov 13, 2018
IPCA Laboratories Ltd. — Marketing Organization
2020s
- Feb 20, 2020
Leading Pharma Llc — Marketing Organization
- Jun 3, 2020
Mayne Pharma — Marketing Organization
- Jun 3, 2020
Dr. Reddy's Laboratories — Marketing Organization
- Sep 29, 2020
Accord Research — Marketing Organization
- Sep 29, 2020
Accord Research — NDA Secondary Org
- Oct 6, 2020
Specgx Llc — Marketing Organization
- Oct 6, 2020
International Medication — Marketing Organization
- Oct 6, 2020
Mallinckrodt (2013) — Marketing Organization
- Oct 21, 2020
Pharma Life Sciences LLC — Marketing Organization
- Oct 21, 2020
Eci Pharmaceuticals Llc — Marketing Organization
- Oct 21, 2020
Chartwell Pharmaceuticals — Marketing Organization
- Jan 27, 2021
Winder Labs Llc — Marketing Organization
- Nov 26, 2021
Apotex — Marketing Organization
- Jan 26, 2022
Amneal Pharmaceuticals — Marketing Organization
- Mar 15, 2022
Bausch & Lomb — Marketing Organization
- Mar 15, 2022
Bausch Health Companies — NDA Secondary Org
- May 26, 2022
Sankyo — Marketing Organization
- May 26, 2022
Daiichi Sankyo — Marketing Organization
- Nov 4, 2022
Medefil — Marketing Organization
- Jan 8, 2024
Mankind Pharma — Marketing Organization
- Apr 29, 2024
Somerset Pharmaceuticals — Marketing Organization
Indications
Approved for
Studied for
- Acute Pain · Phase 4
- Adrenergic Antagonists · Phase 4
- Amblyopia · Phase 4
- Amyotrophic Lateral Sclerosis · Phase 2
- Anesthesia · Phase 4
- Anesthesia and Analgesia · Phase 1/Phase 2
- Anesthesia, General · Phase 3
- Anesthesia, Spinal · Phase 4
- Anisometropia · Phase 3
- Arrhythmias, Cardiac · Phase 4
- Arthroplasty, Replacement, Hip · Phase 3
- Arthroplasty, Replacement, Knee · Phase 3
- Atropine · Phase 1
- Autonomic Nervous System Diseases · Phase 1
- Axial Length, Eye · Phase 2
- Bariatric Surgery · Early Phase 1
- Blood Coagulation · Phase 3
- Blood Pressure · Phase 4
- Bradycardia · Phase 4
- Breast Neoplasms · Phase 2
- Cataract · Phase 4
- Cerebral Palsy · Early Phase 1
- Cesarean Section · Phase 4
- Chest Pain · Phase 3
- Child · Phase 3
- Child, Preschool · Phase 2
- Cognitive Dysfunction · Phase 4
- Delayed Emergence from Anesthesia · Phase 4
- Dental Care for Persons with Disabilities · Phase 4
- Dexmedetomidine · Phase 4
- Digestive System Physiological Phenomena · Phase 1
- Dopamine beta-Hydroxylase · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 1
- Esophageal Achalasia · Phase 4
- Eye Diseases · Phase 4
- Fibrinolytic Agents · Phase 3
- Fractures, Bone · Phase 4
- Gallstones · Phase 4
- Gastrectomy · Early Phase 1
- Gastric Bypass · Early Phase 1
- Gastrointestinal Hormones · Phase 1
- Gastrointestinal Motility · Phase 1
- General Surgery · Phase 4
- Glucagon-Like Peptide 1 · Phase 1
- Gynecology · Phase 4
- Healthy Volunteers · Phase 1
- Heart Arrest · Phase 2
- Hypoglycemia · Early Phase 1
- Hypospadias · Phase 2/Phase 3
- Hypotension · Phase 4
- Hypotension, Orthostatic · Phase 1
- Hypoxia · Phase 4
- Infant, Newborn · Phase 4
- Infant, Premature · Phase 4
- Insecticides · Phase 1
- Insulin Resistance · Early Phase 1
- Intubation · Phase 4
- Intubation, Intratracheal · Phase 4
- Laparoscopy · Phase 4
- Lung Diseases · Phase 4
- Lymphoma · Phase 3
- Muscle Relaxants, Central · Phase 4
- Mydriasis · Phase 4
- Myopia · Phase 4
- Myopia, Degenerative · Phase 3
- Nausea · Phase 4
- Neuromuscular Blockade · Phase 4
- Neuromuscular Blocking Agents · Phase 1/Phase 2
- Ocular Physiological Phenomena · Phase 2
- Organophosphate Poisoning · Phase 2/Phase 3
- Orthostatic Intolerance · Phase 1
- Pain · Phase 4
- Pediatrics · Phase 2/Phase 3
- Perfusion · Phase 2/Phase 3
- Pharmacokinetics · Phase 1
- Pneumonia, Ventilator-Associated · Phase 2
- Poisoning · Phase 4
- Post-Dural Puncture Headache · Phase 4
- Postoperative Complications · Early Phase 1
- Postoperative Nausea and Vomiting · Phase 4
- Prediabetic State · Phase 1
- Pregnancy · Phase 4
- Premedication · Phase 2/Phase 3
- Procedural Sedation · Phase 4
- Refractive Errors · Phase 4
- Regional Blood Flow · Phase 2
- Respiratory Distress Syndrome, Newborn · Phase 4
- Retinal Diseases · Phase 4
- Rhinitis, Allergic, Seasonal · Phase 3
- Sclera · Phase 2
- Scopolamine · Phase 2
- Sialorrhea · Early Phase 1
- Strabismus · Phase 3
- Urinary Tract Infections · Phase 4
- Vasoconstriction · Early Phase 1
- Vasodilation · Early Phase 1
- Vitreous Body · Phase 2
- Vomiting · Phase 4
Mechanism of action
- Muscarinic acetylcholine receptor M2ANTAGONIST
CHRM2 antagonist
Indicated for bradycardia, M2 likely responsible
- Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
Role in regulating gastric secretion, M1 likely involved
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Indicated for mydriasis and regulating gastric secretion, M3 likely involved (main form in iris)
Combination products
atnaa
with pralidoxime
Also known as duodote
atropine and demerol
with meperidine
Also known as meperidine and atropine sulfate
enlon-plus
with tension
lomotil
with diphenoxylate
Also known as colonai, di-atro, logen, lonox, lo-trol
motofen
with difenoxin
Also known as motofen half-strength
Approval history
- approvedPriority reviewSep 15, 1960
Chemistry & pharmacology
SMILES
CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2- Mol. weight
- 289.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL517712 ↗
- WikipediaAtropine ↗
- NCATS7C0697DR9I ↗
- ChEMBLCHEMBL2146146 ↗
- ChEMBLCHEMBL1697729 ↗
Also known as
- [(1s,5r)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
- [(1s,5r)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
- (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
- (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
- 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
- 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
- 8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
- 8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
- anaspaz
- anaspaz
- atroject
- atropen
- atropen
- atropen
- atrophate
- atropin
- atropin
- atropin
- atropina
- atropina
- atropine
- atropine
- atropine
- atropine
- atropine
- atropine
- atropine
- atropine
- atropine
- atropine
- atropine
- (+-)-atropine
- (+-)-atropine
- (+/-)-atropine
- (±)-atropine
- (±)-atropine
- (−)-atropine
- (−)-atropine
- atropine sulfate
- atropine sulfate
- atropine sulfate
- atropine sulfate
- atropine sulfate
- atropine sulfate ansyr plastic syringe
- atropine sulfate ansyr plastic syringe
- atropine sulfate monohydrate
- atropine sulphate
- atropine sulphate
- atropinum
- atropinum
- atropinum sulphuricum
- dl-hyoscyamine
- dl-hyoscyamine
- dl-hyoscyamine
- dl-tropyltropate
- dl-tropyltropate
- (+-)-hyoscyamine
- (+-)-hyoscyamine
- (±)-hyoscyamine
- (±)-hyoscyamine
- isopto atropine
- isopto atropine
- l-tropine tropate
- l-tropine tropate
- mydriasine
- mydriasine
- (r)-atropine
- (+,-)-tropyl tropate
- (+,-)-tropyl tropate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07271875 | Phase 3 | Jan 1, 2026 | Xijing Hospital |
| NCT07095894 | Phase 3 | Jan 1, 2026 | Jaeb Center for Health Research, Vanderbilt University |
| NCT07253428 | N/A | Oct 30, 2025 | Ain Shams University |
| NCT07164092 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2025 | Mansoura University |
| NCT07268586 | Phase 4 | Aug 1, 2025 | Ain Shams University |
| NCT07028827 | Phase 3 | Jul 1, 2025 | Consorzio per Valutazioni Biologiche e Farmacologiche, Ocus Innovation Ireland Limited |
| NCT07176949 | N/A | Jun 1, 2025 | Shanghai Eye Disease Prevention and Treatment Center |
| NCT06922097 | N/A | Apr 7, 2025 | University of Hamburg |
| NCT06765603 | Phase 2 | Feb 1, 2025 | Singapore National Eye Centre |
| NCT06389110 | Phase 3 | Dec 30, 2024 | Laboratorios Sophia S.A de C.V. |
| NCT06667037 | N/A | Nov 30, 2024 | Tianjin Medical University |
| NCT06794450 | Phase 1/Phase 2 (Phase 2) | Nov 5, 2024 | Padjadjaran University |
| NCT06265454 | Phase 2 | Sep 1, 2024 | Ain Shams University |
| NCT06579287 | Phase 2 | Aug 31, 2024 | Sunhawk Vision Biotech, Inc. |
| NCT06200194 | Phase 2 | Aug 1, 2024 | National Yang Ming Chiao Tung University Hospital |
| NCT06450132 | Phase 4 | Aug 1, 2024 | Ohio State University |
| NCT06493838 | Phase 4 | Jul 15, 2024 | Minia University |
| NCT06358755 | Phase 2 | Jul 1, 2024 | The Hong Kong Polytechnic University, The University of Hong Kong |
| NCT06708156 | Phase 3 | Jun 15, 2024 | Capital Medical University, Government of China, Seefunge Pharmaceutical Technology Co., Ltd. |
| NCT06366087 | Phase 1 | Apr 15, 2024 | Allucent, Department of Health and Human Services, Rho, Inc. |
Organizations
Research & Development (184)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jaeb Center for Health Research | Academic/Hospital | 9 | 9 | 2 | 1999 |
| National Eye Institute (NEI) | Government | 9 | 1 | 2 | 1999 |
| Shanghai Eye Disease Prevention and Treatment Center | Academic/Hospital | 9 | 9 | 2 | 2019 |
| Jiao Tong University | Academic/Hospital | 7 | 2 | 3 | 2014 |
| Merck | For profit | 7 | 5 | 2 | 2008 |
| Assiut University | Academic/Hospital | 6 | 6 | 3 | 2016 |
| Ain Shams University | Academic/Hospital | 5 | 5 | 4 | 2021 |
| Capital Medical University | Academic/Hospital | 5 | 1 | 3 | 2022 |
| Ohio State University | Academic/Hospital | 5 | 5 | 4 | 2016 |
| The Hong Kong Polytechnic University | Academic/Hospital | 5 | 5 | 2 | 2016 |
| The University of Hong Kong | Academic/Hospital | 5 | 0 | 2 | 2016 |
| Magna Pharmaceuticals, Inc. | For profit | 4 | 4 | 3 | 2009 |
| Seoul National University | Academic/Hospital | 4 | 4 | 3 | 2008 |
| Vanderbilt University | Academic/Hospital | 4 | 3 | 3 | 1996 |
| Johns Hopkins University | Academic/Hospital | 3 | 0 | 2 | 1999 |
| Laboratorios Sophia S.A de C.V. | For profit | 3 | 3 | 2 | 2022 |
| Mansoura University | Academic/Hospital | 3 | 3 | 3 | 2016 |
| Mayo Clinic | Academic/Hospital | 3 | 2 | 3 | 2002 |
| Singapore National Eye Centre | Academic/Hospital | 3 | 3 | 2 | 2006 |
| State University of New York | Academic/Hospital | 3 | 2 | 2 | 2017 |
Marketing (81)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | MKTG | Jan 30, 1987 |
| Able Laboratories | For profit | MKTG | Nov 27, 2000 |
| Accord Research | For profit | MKTG | Sep 29, 2020 |
| Accord Research | For profit | NDA2 | Sep 29, 2020 |
| Akorn, Inc. | For profit | NDA2 | Jul 18, 2014 |
| Alcon | For profit | NDA2 | Dec 1, 2016 |
| Alpharma | For profit | MKTG | — |
| American Cyanamid | For profit | MKTG | Sep 9, 1982 |
| American Home Products | For profit | MKTG | — |
| Amneal Pharmaceuticals | For profit | MKTG | Jan 26, 2022 |
| Ani Pharmaceuticals | For profit | MKTG | Oct 29, 1979 |
| Ani Pharmaceuticals | For profit | MKTG | Oct 29, 1979 |
| Apotex | For profit | MKTG | Nov 26, 2021 |
| Apotex | For profit | SYN | Nov 26, 2021 |
| Ascot Pharmaceuticals | For profit | MKTG | — |
| Bausch & Lomb | For profit | MKTG | Mar 15, 2022 |
| Bausch Health Companies | For profit | MKTG | Mar 5, 1997 |
| Bausch Health Companies | For profit | NDA2 | Mar 15, 2022 |
| Bayshore Pharms Llc | For profit | MKTG | Nov 13, 2018 |
| Chartwell Pharmaceuticals | For profit | MKTG | Oct 21, 2020 |
| Daiichi Sankyo | For profit | MKTG | May 26, 2022 |
| Dr. Reddy's Laboratories | For profit | MKTG | Jun 3, 2020 |
| Eci Pharmaceuticals Llc | For profit | MKTG | Oct 21, 2020 |
| Fosun | For profit | MKTG | Jun 7, 1977 |
| Fresenius | For profit | NDA2 | Jan 26, 2018 |
| G D Searle | For profit | MKTG | Sep 15, 1960 |
| G D Searle | For profit | NDA2 | Oct 19, 1961 |
| Halsey | For profit | MKTG | — |
| Heather Pharma | For profit | MKTG | — |
| Hikma | For profit | SYN | May 3, 1982 |
| Hikma | For profit | MKTG | Mar 15, 1982 |
| Hospira | For profit | NDA2 | Jul 9, 2001 |
| IPCA Laboratories Ltd. | For profit | MKTG | Nov 13, 2018 |
| International Medication | For profit | MKTG | Oct 6, 2020 |
| Inwood Laboratories | For profit | MKTG | Mar 9, 1978 |
| Lannett Company, Inc. | For profit | MKTG | Feb 21, 1978 |
| Leading Pharma Llc | For profit | MKTG | Feb 20, 2020 |
| Leading Pharma Llc | For profit | SYN | Feb 20, 2020 |
| Lederle | For profit | MKTG | Sep 9, 1982 |
| Lumara Health | For profit | MKTG | Jan 27, 1978 |
| MD Pharma | For profit | MKTG | Apr 18, 1977 |
| MMT | For profit | NDA2 | May 15, 1973 |
| Mallinckrodt (2013) | For profit | MKTG | Oct 6, 2020 |
| Mankind Pharma | For profit | MKTG | Jan 8, 2024 |
| Mayne Pharma | For profit | MKTG | Jun 3, 2020 |
| Medefil | For profit | MKTG | Nov 4, 2022 |
| Medpointe | For profit | MKTG | Feb 13, 1978 |
| Meridien Medical Technologies, Inc. | For profit | NDA2 | May 15, 1973 |
| Meridien Medical Technologies, Inc. | For profit | MKTG | Sep 28, 2006 |
| Mylan | For profit | SYN | Nov 17, 1977 |
| Mylan | For profit | SYN | Nov 6, 1991 |
| Mylan | For profit | MKTG | Dec 22, 1978 |
| Mylan | For profit | NDA2 | Nov 6, 1991 |
| Nestle | For profit | NDA2 | Dec 1, 2016 |
| Par Pharmaceuticals | For profit | MKTG | May 2, 2000 |
| Parke-Davis | For profit | MKTG | Jul 17, 1981 |
| Pfizer | For profit | NDA2 | Sep 15, 1960 |
| Pfizer | For profit | NDA | Sep 15, 1960 |
| Pharma Life Sciences LLC | For profit | MKTG | Oct 21, 2020 |
| R&S Pharma | For profit | MKTG | Jul 5, 1977 |
| R.P. Scherer | For profit | MKTG | Apr 6, 1981 |
| Rafa Laboratories | For profit | NDA2 | Jul 9, 2018 |
| Rising Pharmaceuticals | For profit | MKTG | Jul 18, 2014 |
| Roxane Laboratories | For profit | MKTG | — |
| Sankyo | For profit | MKTG | May 26, 2022 |
| Sebela Pharmaceuticals | For profit | MKTG | Jul 14, 1978 |
| Sebela Pharmaceuticals | For profit | NDA2 | Jul 14, 1978 |
| Somerset Pharmaceuticals | For profit | MKTG | Apr 29, 2024 |
| Somerset Pharmaceuticals | For profit | SYN | Jul 1, 2024 |
| Specgx Llc | For profit | MKTG | Oct 6, 2020 |
| Strides Pharma Science | For profit | MKTG | May 2, 2000 |
| Sun Pharmaceuticals | For profit | MKTG | Jun 3, 1977 |
| Superpharm | For profit | MKTG | May 10, 1985 |
| United States Army | Government | NDA2 | Sep 19, 1990 |
| Upsher-Smith Laboratories | For profit | MKTG | Aug 31, 2018 |
| Upsher-Smith Laboratories | For profit | SYN | Mar 29, 1982 |
| Vanguard | For profit | MKTG | Mar 25, 1983 |
| Warner Lambert | For profit | MKTG | Jul 17, 1981 |
| Watson Pharmaceuticals | For profit | MKTG | Jun 22, 1978 |
| West-Ward Pharmaceutical | For profit | MKTG | May 3, 1982 |
| Winder Labs Llc | For profit | MKTG | Jan 27, 2021 |